02755nas a2200349   4500000000100000008004100001260004400042653001500086653002100101653001300122653001300135100001300148700001800161700001300179700001500192700001200207700001400219700001400233700001400247700001300261700001200274700001400286700001200300700001200312700001300324245014200337856006500479300000800544490000700552520183200559022001402391       2025                            d  bSpringer Science and Business Media LLC10aIvermectin10aStrongyloidiasis10aEfficacy10aEthiopia1 aAmare GA1 aWondmagegn YM1 aSetegn A1 aBelayneh M1 aMuche Y1 aMelkamu A1 aMisgana K1 aAshagre A1 aBaylie T1 aJemal M1 aGetinet M1 aFenta A1 aBelew H1 aAdugna A00aEffectiveness of Ivermectin treatment among adult patients infected with Strongyloides stercoralis in East Gojam zone, Northwest Ethiopia  uhttps://link.springer.com/article/10.1186/s12879-025-11070-7  a1-60 v253 a<p><strong>Introduction:&nbsp;</strong>Strongyloidiasis caused by the parasite Strongyloides stercoralis, is a significant public health issue, particularly in low-income countries with inadequate sanitation practices. Ivermectin is the recommended drug by the World Health Organization for treating S. stercoralis infection, but its efficacy in Ethiopia has not been extensively studied. This study aimed to assess the effectiveness of Ivermectin treatment for S. stercoralis infection in adult patients.</p>

<p><strong>Methods:</strong> A cross-sectional study was conducted in government hospitals in northwest Ethiopia from June 2022 to February 2024. A total of 190 patients confirmed to be infected with S. stercoralis were treated with Ivermectin (200&nbsp;µg/kg) for two days. Stool samples were collected two weeks after treatment and analyzed using parasitological concentration techniques.</p>

<p><strong>Results:</strong> The cure rate was 90% among the treated individuals, demonstrating a significant reduction in the prevalence of S. stercoralis infection. Among the cases that were not cured, the majority were older individuals, with a higher proportion (66.8%) residing in rural areas. A small number of non-cured individuals experienced persistent symptoms after treatment. All individuals who successfully cleared the infection were asymptomatic.</p>

<p><strong>Conclusion: </strong>The study found a 90% cure rate for the current 2-day Ivermectin treatment regimen (200&nbsp;µg/kg) against Strongyloides stercoralis in Ethiopia, suggesting the recommended strategy is appropriate. Age, residential area, and other factors have been found to influence treatment outcomes, warranting further investigation into potential resistance factors and optimizing treatment for different populations.</p>
  a1471-2334